Mehmet ÖZDEMİR,
İhsan Hakkı ÇİFTCİ,
Lütfiye ÖKSÜZ,
Mücahide Esra KOÇOĞLU,
Mustafa BERKTAŞ,
Adnan SEYREK,
Emel ÇETİN SESLİ,
Ahmet AYYILDIZ,
Server YAĞCI,
Muhammet Güzel KURTOĞLU,
Mustafa GÜL,
Gülşah AŞIK
7029
Detection of the frequency of PER-1 type extended-spectrum β-lactamase producing Acinetobacter baumannii clinical isolates in Turkey: a multicenter study
Detection of the frequency of PER-1 type extended-spectrum β-lactamase producing Acinetobacter baumannii clinical isolates in Turkey: a multicenter study
Background/aim: β-Lactamases are an important resistance mechanism in Acinetobacter baumannii. Pseudomonas extended-resistance (PER-1) type β-lactamase producing strains have been reported from various geographic locations; however, PER-1 type β-lactamases from Turkish hospitals have not been investigated extensively. The aim of this study was to determine the prevalence of PER-1 type β-lactamases in A. baumannii isolates in various regions of Turkey. Materials and methods: A total of 763 clinical A. baumannii isolates were collected from 9 university hospitals and 2 state hospitals between 2008 and 2011. Molecular amplification of the OXA-51 gene from the A. baumannii genome was performed in order to verify identification of the species. Real-time polymerase chain reaction was used to detect blaPER-1 genes. Results: PER-1 was detected in 24.6% of the isolates. The annual frequencies of the PER-1 enzyme were detected as 52.2%, 35.9%, and 8.3% in 2008, 2009, and 2010, respectively. PER-1 prevalence decreased gradually over time. The differences observed in PER-1 prevalence among the regions of Turkey were statistically significant (chi-square test; P < 0.001). Conclusion: These data demonstrate that the frequency of detection of PER-1 type β-lactamases in A. baumannii species has decreased in Turkey. However, the increased carbapenem resistance, together with multidrug resistance, has created a worrisome situation regarding this pathogen.
___
- 1. Bergogne-Berezin E. Resistance of Acinetobacter spp. to antimicrobials: overview of clinical resistance patterns and therapeutic problems. In: Bergogne-Berezin E, Joly-Guillou ML, Towner KJ, editors. Acinetobacter: Microbiology, Epidemiology, Infections, Management. Boca Raton, FL, USA: CRC Press; 1996. pp. 133183.
- 2. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358: 12711281.
- 3. Towner KJ. Molecular basis of antibiotic resistance in Acinetobacter spp. In: Gerisher U, editor. Acinetobacter Molecular Biology. Norfolk, UK: Caister Academic Press; 2008. pp. 322343.
- 4. Brown S, Young HK, Amyes SGB. Characterisation of OXA-51, a novel class D cephalosporinase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin Microbiol Infect 2005; 11: 1523.
- 5. Nordman P, Ronco E, Naas T, Duport C, Michel Briand Y, Labia R. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 962969.
- 6. Vahaboglu H, Ozturk R, Aygun G, Coskunkan F, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Oktun M. Widespread of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41: 22652269.
- 7. Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H. PER- 1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett 2005; 249: 241245.
- 8. Erac B, Gulay Z. Molecular epidemiology of PER-1 extended spectrum β-lactamase among gram-negative bacteria isolated at a tertiary care hospital. Folia Microbiol 2007; 52: 535541.
- 9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2007.
- 10. Bogner PN, Killeen AA. Extraction of nucleic acids. In: Coleman WB, Tsongalis GJ, editors. Molecular Diagnostics: For the Clinical Laboratorian. New York, NY, USA: Humana Press; 2007. pp. 2530.
- 11. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 2008; 52: 38373843.
- 12. Turner PJ, Greenhalgh JM; MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 19972000. Clin Microbiol Infect 2003; 9: 563567.
- 13. Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N, Cevik MA. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008; 12: 1621.
- 14. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8: 751762.
- 15. Kean SJ. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008; 68: 20212057.
- 16. Pagani L, Mantengoli E, Migliavacca R, Nucleo E, Pollini S, Spalla M, Daturi R, Romero E, Rossolini GM. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase in northern Italy. J Clin Microbiol 2004; 42: 25232529.
- 17. De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J, Nordmann P. Prospective survey of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002; 46: 30313034.
- 18. Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum beta-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother 2006; 58: 178182.
- 19. Miro E, Mirelis B, Navarro F, Rivera A, Mesa RJ, Roig MC, Gomez L, Coll P. Surveillance of extended-spectrum betalactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother 2005; 56: 1152 1155.
- 20. Empel J, Filczak K, Mrowka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol 2007; 45: 28292834.
- 21. Naas T, Nordmann P, Heidt A. Intercountry transfer of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter baumannii from Romania. Int J Antimicrob Agents 2007; 29: 226228.
- 22. Yamano Y, Nishikawa T, Fujimura T, Yutsudou T, Tsuji M, Miwa H. Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem. J Antibiot (Tokyo) 2006; 59: 791796.
- 23. Lee S, Park YJ, Kim M, Lee HK, Han K, Kang CS, Kang MW. Prevalence of Ambler class A and D beta-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 2005; 56: 122127.
- 24. Jeong SH, Bae IK, Kwon SB, Lee K, Yong D, Woo GJ, Lee JH, Jung HI, Jang SJ, Sung KH et al. Investigation of a nosocomial outbreak of Acinetobacter baumannii producing PER-1 extended spectrum beta-lactamase in an intensive care unit. J Hosp Infect 2005; 59: 242248.
- 25. Eraç B, Hoşgör-Limoncu M, Ermertcan Ş, Taşlı H, Aydemir Ş. Prevalence of blaPER-1 and integrons in ceftazidime-resistant Gram-negative bacteria at a university hospital in Turkey. Jpn J Infect Dis 2013; 66: 146148.
- 26. Vahaboglu H, Coskunkan F, Tansel O, Ozturk R, Sahin N, Koksal I, Kocazeybek B, Tatman-Otkun M, Leblebicioglu H, Ozinel MA et al. Clinical importance of extended-spectrum ß-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microb 2001; 50: 642 645.